Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus NORMINEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus NORMINEST FE.
ENOVID-E vs NORMINEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (FSH, LH). Increases cervical mucus viscosity, reducing sperm penetration. Norethindrone acetate is metabolized to norethindrone, which binds to progesterone receptors; ethinyl estradiol binds to estrogen receptors, providing contraceptive effect and cycle control.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
1 tablet orally once daily, starting on day 1 of menstrual cycle; each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (21 active tablets) followed by 7 ferrous fumarate tablets.
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours. Clinical context: steady-state in 5-7 days.
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal 60-80% as metabolites, fecal 20-30% via bile, unchanged drug <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive